Join the club for FREE to access the whole archive and other member benefits.


Pharmaceutical company focusing to cancer and neurology drugs.

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina.

Visit website:



Eisai News

Eisai's Lecanemab drug proves to slowdown Alzheimer's disease, unlike aducanumab drug

BBC - 28-Sep-2022

Historic moment for dementia research-large clinical trial to successfully slow cognitive decline


Biogen's Alzheimer's drug trials halted

CNN - 21-Mar-2019

Another promising candidate not making it to the finish line